4D Molecular Therapeutics, Inc. FDMT
Nov 12, 2026, 2:18 PM EST
- YTD
- +64.73%
- 1 year
- +12.63%
FDMT free cash flow history
Free cash flow is operating cash flow minus capital expenditure outflow. It can be negative; it is not the same as earnings.
-109,618,000 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Capital expenditure here is net of asset disposals, so free cash flow can be higher than a figure that subtracts gross purchases.
Scroll the table to see all values →
| Fiscal period | Period end | Free cash flow | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | -109,618,000 | 28,753,000 | Not meaningful |
| FY 2024 | 2024-12-31 | -138,371,000 | -59,808,000 | Not meaningful |
| FY 2023 | 2023-12-31 | -78,563,000 | 19,658,000 | Not meaningful |
| FY 2022 | 2022-12-31 | -98,221,000 | -19,977,000 | Not meaningful |
| FY 2021 | 2021-12-31 | -78,244,000 | -26,335,000 | Not meaningful |
| FY 2020 | 2020-12-31 | -51,909,000 | -11,995,000 | Not meaningful |
| FY 2019 | 2019-12-31 | -39,914,000 | -23,248,000 | Not meaningful |
| FY 2018 | 2018-12-31 | -16,666,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-05-22T14:43:43.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.